NasdaqGS:QUREBiotechs
Will QURE’s AMT-130 Regulatory Momentum Offset Mounting Losses And Share Dilution Risk?
In the past week, uniQure N.V. reported Q2 2026 results showing revenue of US$5.84 million alongside a much larger quarterly net loss of US$81.06 million, while also filing a US$12.83 million shelf registration for 350,000 ordinary shares tied to its employee share plan.
At the same time, the company advanced its regulatory plans for AMT-130 in Huntington’s disease and highlighted promising early data in epilepsy and Fabry programs, framing a contrast between widening losses and progress in...